AIMD Ainos, Inc. logo

AIMD Ainos, Inc.

Healthcare
$1.53-3.16%ClosedMarket Cap: $6.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

1.62

P/S

382.50

EV/EBITDA

-1.81

DCF Value

$-2.66

FCF Yield

-63.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

-26296.8%

Operating Margin

-72393.5%

Net Margin

-76996.2%

ROE

-160.6%

ROA

-63.2%

ROIC

-73.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$161.00$-2.5M$
Q4 null$11.1K$-4.5M$
FY null$124.2K$-14.8M$
Q3 null$2.2K$-2.9M$

Analyst Ratings

View All

Consensus

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
chiang yao-chungdirector
BuyWed May 20
chiang yao-chungdirector
BuyWed May 20
chiang yao-chungdirector
BuyThu May 07
chiang yao-chungdirector
BuyFri May 01
chiang yao-chungdirector
BuyFri May 01

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

2.29

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

Peers